Crescendo Biologics announces presentations at AACR 2022

Cambridge, UK, 9 March 2022 – Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces that two abstracts have been accepted for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting. The meeting is to be held in New Orleans, USA between 8-13 April 2022, and members of the Crescendo Biologics team will attend the conference in person and will be available to discuss the posters.

"CB307 is our first-in-class, half-life extended, CD137xPSMA bispecific, and we are looking forward to sharing the preclinical pharmacology as well as the overall aim and study design of the ongoing clinical trial for this novel molecule," commented **Dr Kenji Hashimoto, Chief Medical Officer at Crescendo**. "CB307 was created to deliver a safer and more durable T cell response to cancer. It does so by providing the costimulatory signal needed to enhance T cell activation and drive proliferation, but only in the tumour microenvironment, because the costimulatory signal via CD137 agonism is conditional upon the presence of prostate specific membrane antigen (PSMA), a clinically-validated tumour-associated antigen."

Details of the abstracts:

Pierce, AJ et al, ***CB307: a novel selective CD137 agonist for enhancement of immune cell responses to PSMA+ tumors*** *Tuesday 12 April 2022 (9:00 am – 12.30 pm CDT), Therapeutic Antibodies 1, Poster Section 37*

De Bono, JS et al, ***A Phase 1 open-label, dose escalation and expansion trial to investigate the safety, pharmacokinetics and pharmacodynamics of CB307, a trispecific Humabody® T-cell enhancer, in patients with PSMA+ advanced and/or metastatic solid tumors (POTENTIA)*** *Tuesday 12 April 2022 (9:00 am – 12.30 pm CDT), Phase I Trials in Progress 1, Poster Section 34*

-Ends-

For more information, please contact:

Crescendo Biologics

Michael Booth, CFO
+ 44 (0)1223 497140
investors@crescendobiologics.com
media@crescendobiologics.com

Instinctif Partners

Melanie Toyne-Sewell, Katie Duffell, Nathan Billis
+ 44 (0)20 7457 2020
crescendo@instinctif.com

About Crescendo Biologics

Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics.

Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel half-life extended CD137 x PSMA Humabody® for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity, and the clinical programme for CB307 is underway in patients with PSMA positive solid tumours (NCT04839991).

The Company's ability to develop multi-functional Humabody® therapeutics is based on its unique, patent protected, transgenic mouse platform generating fully human V_H domain building blocks (Humabody® V_H). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel pharmacology and superior bio-distribution. This can lead to larger therapeutic windows compared to conventional IgG approaches. Humabody®-based formats can also be applied across a range of non-cancer indications.

Beyond Crescendo's proprietary pipeline, the Company has global, multi-target discovery and development collaborations with both Takeda and BioNTech; a clinical development partnership for CB213 (a PD-1xLAG-3 multi-specific Humabody®) with Cancer Research UK; and an exclusive, worldwide licensing agreement with Zai Lab for ZL-1102 (formerly CB001, an anti-IL-17A targeting Humabody®), which is expected to enter global Phase 2 clinical development for patients with psoriasis.

Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, BioNTech, Takeda and Quan Capital.

For more information, please visit www.crescendobiologics.com and follow @HUMABODY.